OBJECTIVE: Limited clinical trials have validated the hypothesis of controlling graft-versus-host disease (GVHD) arising from stem cell transplant utilizing suicidal T-lymphocytes that have been transduced to express the HSV-TK gene. However, clinical utility has been limited by diminished T-cell function arising from the production process. To evaluate strategies for harnessing the graft-versus-leukemia (GVL) effect while improving the safety and function of suicidal lymphocytes, we have developed techniques to produce fully functional, retrovirally transduced, HSV-TK-positive murine T cells (TK+TC). METHODS: Utilizing a murine major histocompatibility complex-matched transplant model, we evaluated the ability of TK+TC to generate a GVL effect and the ability to control GVHD in experiments where we varied the dose of TK+TC, ganciclovir (GCV) dose, the start of GCV administration (day 4, 7, 10, 13, 15, or 19) posttransplantation, and the GCV administration route (osmotic pump versus intraperitoneal). RESULTS: At TK+TC doses in excess of the standard lethal dose (SLD) of unmanipulated T-cells, GCV administration completely (2 x SLD) and partially (4 x SLD) controlled GVHD. Additionally, GVHD remained reversible despite delaying administration of GCV for a week after GVHD developed. Importantly, GVHD was controlled with a 1-log but not 2-log reduction in GCV dose, and this "partial suicide" preserved more circulating TK+TC compared with standard-dose GCV. Survival of leukemia-positive mice receiving TK+TC and GCV was significantly increased compared with control cohorts not receiving GCV or transplanted with unmanipulated T cells, thereby demonstrating a GVL effect. CONCLUSION: Retrovirally transduced suicidal lymphocytes generate a potent GVL effect while simultaneously enabling control of GVHD, which results in improved leukemia and GVHD-free survival.
OBJECTIVE: Limited clinical trials have validated the hypothesis of controlling graft-versus-host disease (GVHD) arising from stem cell transplant utilizing suicidal T-lymphocytes that have been transduced to express the HSV-TK gene. However, clinical utility has been limited by diminished T-cell function arising from the production process. To evaluate strategies for harnessing the graft-versus-leukemia (GVL) effect while improving the safety and function of suicidal lymphocytes, we have developed techniques to produce fully functional, retrovirally transduced, HSV-TK-positive murine T cells (TK+TC). METHODS: Utilizing a murine major histocompatibility complex-matched transplant model, we evaluated the ability of TK+TC to generate a GVL effect and the ability to control GVHD in experiments where we varied the dose of TK+TC, ganciclovir (GCV) dose, the start of GCV administration (day 4, 7, 10, 13, 15, or 19) posttransplantation, and the GCV administration route (osmotic pump versus intraperitoneal). RESULTS: At TK+TC doses in excess of the standard lethal dose (SLD) of unmanipulated T-cells, GCV administration completely (2 x SLD) and partially (4 x SLD) controlled GVHD. Additionally, GVHD remained reversible despite delaying administration of GCV for a week after GVHD developed. Importantly, GVHD was controlled with a 1-log but not 2-log reduction in GCV dose, and this "partial suicide" preserved more circulating TK+TC compared with standard-dose GCV. Survival of leukemia-positive mice receiving TK+TC and GCV was significantly increased compared with control cohorts not receiving GCV or transplanted with unmanipulated T cells, thereby demonstrating a GVL effect. CONCLUSION: Retrovirally transduced suicidal lymphocytes generate a potent GVL effect while simultaneously enabling control of GVHD, which results in improved leukemia and GVHD-free survival.
Authors: Sylvie Coito; Delphine Sauce; Anne Duperrier; Jean-Marie Certoux; Mark Bonyhadi; Alexis Collette; Klaus Kuehlcke; Patrick Hervé; Pierre Tiberghien; Eric Robinet; Christophe Ferrand Journal: Stem Cells Dev Date: 2004-02 Impact factor: 3.272
Authors: Britt E Anderson; Jennifer McNiff; Jun Yan; Hester Doyle; Mark Mamula; Mark J Shlomchik; Warren D Shlomchik Journal: J Clin Invest Date: 2003-07 Impact factor: 14.808
Authors: Richard K Burt; William R Drobyski; Tatiana Seregina; Ann Traynor; Yu Oyama; Carolyn Keever-Taylor; Jacob Stefka; Timothy M Kuzel; Mary Brush; Julianne Rodriquez; Willam Burns; Lucinda Tennant; Charles Link Journal: Exp Hematol Date: 2003-10 Impact factor: 3.084
Authors: Catherine C Matte; James Cormier; Britt E Anderson; Ioanna Athanasiadis; Jinli Liu; Stephen G Emerson; Warren Pear; Warren D Shlomchik Journal: Blood Date: 2004-02-24 Impact factor: 22.113
Authors: Amer M Najjar; Pallavi R Manuri; Simon Olivares; Leo Flores; Tiejuan Mi; Helen Huls; Elizabeth J Shpall; Richard E Champlin; Nashaat Turkman; Vincenzo Paolillo; Jason Roszik; Brian Rabinovich; Dean A Lee; Mian Alauddin; Juri Gelovani; Laurence J N Cooper Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488
Authors: Gianpietro Dotti; Mei Tian; Barbara Savoldo; Amer Najjar; Laurence J N Cooper; James Jackson; Amanda Smith; Osama Mawlawi; Rajesh Uthamanthil; Agatha Borne; David Brammer; Vincenzo Paolillo; Mian Alauddin; Carlos Gonzalez; David Steiner; William K Decker; Frank Marini; Steven Kornblau; Catherine M Bollard; Elizabeth J Shpall; Juri G Gelovani Journal: Mol Imaging Date: 2009 Jul-Aug Impact factor: 4.488